Protective effect of losartan on injury induced by ox-LDL in endothelial cells and the relationship with asymmetric dimethylarginine

Journal of Central South University (Medical Sciences)

Volumn 31, Issue 1, 2006, Pages 66-69

  Xie, Qi Ying ^a   Sun, Ze Lin ^a   Chen, Mei Fang ^a   Yang, Tian Lun ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Asymmetric dimethylarginine; Dimethylarginine dimethylaminohydrolase; Endothelial cells; Losartan; Oxidative low density lipoprotein

Indexed keywords

DIMETHYLARGININASE; LACTATE DEHYDROGENASE; LOSARTAN; LOW DENSITY LIPOPROTEIN; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL CULTURE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; INCUBATION TIME; UMBILICAL VEIN;

AMIDOHYDROLASES; ARGININE; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; HUMANS; L-LACTATE DEHYDROGENASE; LIPOPROTEINS, LDL; LOSARTAN; NITRIC OXIDE; PROTECTIVE AGENTS; UMBILICAL VEINS;

EID: 33644912041     PISSN: 16727347     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Boger RH, Bode-Boger SM, Tsao PS, et al. An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes[J]. J Am Coll Cardiol, 2000, 36(7):2287-2295.
2. Curgunlu A, Uzun H, Bavunoglu I, et al. Increased circulating concentrations of asymmetric dimethylarginine (ADMA) in white coat hypertension[J]. J Hum Hypertens, 2005, 19(8):629-633.
3. Krempl TK, Maas R, Sydow K, et al. Elevation of asymmetric dimethylarginine in patients with unstable angina and recurrent cardiovascular events[J]. Eur Heart J, 2005, 26(18):1846-1851.
4. Bae SW, Stuhlinger MC, Yoo HS, et al. Plasma asymmetric dimethylarginine concentrations in newly diagnosed patients with acute myocardial infarction or unstable angina pectoris during two weeks of medical treatment[J]. Am J Cardiol, 2005, 95(6):729-733.
5. Fliser D, Buchholz K, Haller H. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation[J]. Circulation, 2004, 110(9):1103-1107.
6. Koh KK, Han SH, Chung WJ, et al. Comparison of effects of losartan, irbesartan, and candesartan on flow-mediated brachial artery dilation and on inflammatory and thrombolytic markers in patients with systemic hypertension[J]. Am J Cardiol, 2004, 93 (11):1432-1435, A1410.
7. Guan S, Wang B. Effects of fosinopril and valsartan on expressions of ICAM-1 and NO in human umbilical vein endothelial cells[J]. Chin Med J (Engl), 2003, 116(6):923-927.
8. Paroni R, Fermo I, Fiorina P, et al. Determination of asymmetric and symmetric dimehylarginines in plasma of hyperhomocysteinemic subjects[J]. Amino Acids, 2005, 28(4):389-394.
9. Yang TL, Chen MF, Luo BL, et al. Fenofibrate decreases asymmetric dimethylarginine level in cultured endothelial cells by inhibiting NF-kappaB activity[J]. Naunyn Schmiedebergs Arch Pharmacol, 2005, 371(5):401-407.
10. Ito A, Tsao PS, Adimoolam S, et al. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase[J]. Circulation, 1999, 99(24):3092-3095.
11. Delles C, Schneider MP, John S, et al. Angiotensin converting enzyme inhibition and angiotensin II AT1-receptor blockade reduce the levels of asymmetrical N(G), N(G)-dimethylarginine in human essential hypertension[J]. Am J Hypertens, 2002, 15(7 Pt 1):590-593.
12. Napoli C, Sica V, de Nigris F, et al. Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension[J]. Am Heart J, 2004, 148(1):172-179.
13. Jiang JL, Jiang DJ, Tang YH, et al. Effect of simvastatin on endothelium-dependent vaso-relaxation and endogenous nitric oxide synthase inhibitor[J]. Acta Pharmacol Sin, 2004, 25(7):893-901.